

Applicant : William J. Watkins  
Serial No. : 10/583,683  
Filed : April 11, 2007  
Page : 3 of 4

Attorney's Docket No.: 01692.315US2

XII. Claim 65 which is drawn to a method of treating cancer with compounds of formula (I), wherein L1 is nitrogen and L2 is nitrogen and form a substituted [1,2,3]triazolo[4,5-d]pyrimidine.

**REMARKS**

No claims are added and no claims are amended. As a result, claims 1-55, 57-65 and 71 are pending.

In response to the Supplemental Restriction Requirement Applicant hereby elects Group II, directed to compounds of formula (I) wherein L1 is nitrogen and L2 is carbon and thus form a substituted purine.

**Telephonic Interview Summary**

Applicant thanks Examiner Susanna Moore for the courtesy of a telephone interview on 19 March 2008, with Applicants' representative Robert J. Harris (Reg. No. 37,346). During the interview, the restriction requirements for the two co-pending applications 10/583,683 and 11/021,114 were discussed. In light of this discussion the Examiner noted that she will issue a supplemental restriction requirement for the instant application and clarify the restriction requirement for co-pending application 11/021,114, so that they are consistent.

The above account is believed to be a complete and accurate summary of the telephonic interview as required by 37 C.F.R. 1.133. If the Examiner believes that this summary is inaccurate or incomplete, Applicant respectfully requests that the Examiner point out any deficiencies in his next communication so that Applicant can amend or supplement the interview summary.

Applicant thanks the Examiner for issuing the Supplemental Restriction Requirement for the instant application. For the Examiner's convenience, Applicant would like to point out what are believed to be typographical errors in supplemental restriction groups V-VIII and XI. In supplemental restriction groups I-IV, IX-X and XII the assignments of carbon and nitrogen for each L1 and L2 match the name assigned for the core heterocyclic template (e.g. L1, L2 = carbon for pyrrolo[2,3-d]pyrimidine in group I). However, for supplemental restriction groups V-VIII and XI the assignments for L1 and L2 do not match the named heterocyclic template. In the table below Applicant provides proposed amended designations for L1 and L2 that are believed to correlate with the named heterocyclic template for the respective restriction group.

Applicant : William J. Watkins  
Serial No. : 10/583,683  
Filed : April 11, 2007  
Page : 4 of 4

Attorney's Docket No.: 01692.315US2

Supplemental Restriction Group	Proposed L1/L2
V	L1 is carbon and L2 is carbon
VI	L1 is nitrogen and L2 is carbon
VII	L1 carbon and L2 is nitrogen
VIII	L1 is nitrogen and L2 is nitrogen
XI	L1 is carbon and L2 is nitrogen

Applicant requests that the Examiner clarify the L1/L2 designations for restriction groups V-VIII and XI in her next communication.

The Examiner is invited to contact Applicant's Representative at the below-listed telephone number if there are any questions regarding this Response or if prosecution of this application may be assisted thereby.

**If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 50-3503. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extension fees to Deposit Account 50-3503.**

Respectfully submitted,


William J. Watkins

By his Representatives,

Viksnins Harris & Padys PLLP  
**Customer Number 53864**  
PO Box 111098  
St. Paul, MN 55111-1098  
(952) 876-4092

Date: 4-25-08

By:

  
Robert J. Harris  
Reg. No. 37,346